Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6
Raymond James analyst Thomas Deal initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $6.
Share
Why It Matters
A big investment bank started watching Palisade Bio and thinks it looks good. When experts start paying attention to a smaller company, it often means they see something interesting happening.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.